ImmunoPrecise Antibodies (NASDAQ:IPA) reported quarterly losses of $(0.15) per share which missed the analyst consensus estimate of $(0.13) by 15.38 percent. The company reported quarterly sales of $5.300 million which missed the analyst consensus estimate of $6.750 million by 21.48 percent. This is a 24.35 percent increase over sales of $4.262 million the same period last year.